期刊文献+

托伐普坦类似物的合成及其利尿活性 被引量:2

Synthesis and Diuretic Activities of Tolvaptan Analogues
下载PDF
导出
摘要 以2-氨基-5-氯苯甲酸甲酯为原料,经五步反应制得7-氯-5-氧代-2,3,4,5-四氢-1H-苯氮杂卓艹(2);2与5-硝基吡啶-2-甲酰氯(或对硝基苯甲酰氯)发生N-酰化反应,再经SnCl2还原制得关键中间体4a(或4b);在4的氨基上引入取代苯甲酰基或苯磺酰基合成了15个具有潜在AVP-V2受体抑制作用的新型托伐普坦类似物(5a~5k,6b,6i,7b和8d),其结构经1H NMR,IR和MS表征。SD大鼠利尿活性试验表明,5~8均有一定的利尿活性,且部分化合物活性较高。 7-Chloro-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine(2) was prepared by a five-step reaction from methyl 2-amino-5-chlorobenzoate.Two key intermediates,4a and 4b,was prepared by N-acetylation of 2 with 5-nitrylpyridine-2-carbamoyl chloride or p-nitrylbenzoyl chlorid,then reduction in the presence of SnCl2.Fifteen novel potential inhibition of the AVP-V2 receptors,tolvaptan derivatives(5a~5k,6b,6i,7b and 8d) were synthesized by introducing substituted-benzoyl or substituted-phenyl-sulfonyl at amino of 4.The structures were characterized by 1H NMR,IR and MS.The SD rats diuretic test showed that some of them exhibited better diuretic activities.
出处 《合成化学》 CAS CSCD 北大核心 2012年第5期543-549,共7页 Chinese Journal of Synthetic Chemistry
基金 国家重大新药创制专项(2011ZX09401-009)
关键词 托伐普坦类似物 AVP-V2受体拮抗剂 合成 利尿活性 tolvaptan derivative; AVP-V2 receptor antagonist; synthesis; diuretic activity;
  • 相关文献

参考文献11

  • 1Ghall J K, Hamad B, Yasothan U, et al. Tolvaptan [J]. Drug Discov,2009,8(8) :611.
  • 2Otsuka. America Pharmaceutical. inc. SAMSCA TM(tolvaptan) [ D ]. Otsuka America Pharmaceutical Co Ltd. ,2009.
  • 3Decaux G, Soupart A, Vassart G. Non-pepfide arglnine-vasopressin antagonists : The vaptans [ J ]. Lancet, 2008,371 (9624) : 1624 - 1632.
  • 4Schrier R W, Gross P, Gheorghiade M, et al. Salt investigators Tolvaptan, a selective oral vasopressin V2receptor antagonist for hyponatremia [ J ]. N Engl J Meal,2006,355:2099 - 2112.
  • 5Yoshitaka Y, Shigeki N, Shuji I, et al. OPC-41061 ,a highly potent human vasopressin V2-receptor antagonlst: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats[ J]. J Pharmacol Exp Ther, 1998,287 (3) : 860 - 867.
  • 6Gheorghiade M, Konstam M A, Burnett J C, et al. For the effecacy of vasopressln antagonism in heart failure: Outcome study with tolvaptan(EVEREST) investigators [ J]. J Am Med Assoc,2007,297 : 1332 - 1343.
  • 7小川英则,宫本寿,近藤一见,等.苯并杂环化合物[P].CN1051038A,1991.
  • 8Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5-hydroxy-1- [ 2-methyl-4- ( 2-methylbenzoyl-amino ) benzoyl ]- 2, 3,4, 5-tetrahydro-1H-1-benzazepine ( OPC-41061 ) : A potent,orally active nonpeptide arginine vasopressin V2 receptor antagonist [ J ]. Bioorg Med Chem, 1999,7 ( 8 ) : 1743 - 1754.
  • 9杨妙,帅军,刘默,刘登科,王平保.7-氯-5-氧代-2,3,4,5-四氢-1H-1-苯并氮杂的合成[J].中国医药工业杂志,2009,40(9):648-650. 被引量:6
  • 10杨传伟,穆帅,刘颖,王平保,刘登科.托伐普坦的合成[J].中国医药工业杂志,2011,42(2):90-92. 被引量:6

二级参考文献6

  • 1Josiassen RC, Goldman M, Jessani M, et al. Doubleblind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia [J]. Biol Psychiatry, 2008, 64(12): 1097-1100.
  • 2Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia [J]. New Engl J Med, 2006, 355(20): 2099-2112.
  • 3Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5-hydroxy- 1- [2-methyl-4- (2-methylbenzoyl-amino) benzoyl] -2,3,4,5- tetrahydro- 1 H- 1 -benzazepine (OPC-41061) : a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist [J]. Bioorg Med Chem, 1999, 7 (8) : 1743-1754.
  • 4Cordero-Vargas A, Quiclet-Sire B, Zard SZ. A flexible approach for the preparation of substituted benzazepines: application to the synthesis of tolvaptan [J]. Bioorg Med Chem, 2006, 14(18):6165-6173.
  • 5杨妙,帅军,刘默,刘登科,王平保.7-氯-5-氧代-2,3,4,5-四氢-1H-1-苯并氮杂的合成[J].中国医药工业杂志,2009,40(9):648-650. 被引量:6
  • 6李凡,侯兴普,李林,律涛,杜玉民.抗帕金森病药Istradefylline的合成[J].中国医药工业杂志,2010,41(4):241-243. 被引量:5

共引文献10

同被引文献17

  • 1Jao G T, Chiong J R. Hyponatremia in acute decom- pensated heart failure: Mechanisms, prognosis and treatment options [ J ]. Clinical Cardiology, 2010, 33 (11) :666 -671.
  • 2Zenenberg R, Carluccio A, Merlin M. Hyponatremia: Evaluation and management [J]. Hospital Practice, 2010,38(1) :89 -96.
  • 3Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC- 31260 on congestive heart failure in conscious dogs [J] . American Journal of Physiology-Heart and Circulatory Physiology,1994,267(6) :H2245 -H2254.
  • 4Verbalis J G. A VP receptor antagonists as aquaretics , Review and assessment of clinical data [J]. Cleveland Clinic Journal of Medicine ,2006,73 (Suppl 3) : S24.
  • 5Geha R S, Meltzer E O. Desloratadine , A new, nonsedating, oral antihistamine [J]. Journal of Allergy and Clinical Immunology,2001,107(4) :751 -762.
  • 6Liu W, Zhou J, Zhang T, et al. Design and synthesis of thiourea derivatives containing a benzo [5 ,6] cyclohepta [1 , 2-b] pyridine moiety as potential antitumor and anti-inflammatory agents [J] . Bioorganic & Medicinal Chenristry Letters,2012,22(8) :2701 -2704.
  • 7Liu G Z, Xu H W, Chen G W, et al. Stereoselective synthesis of desloratadine derivatives as antagonist of histamine [J]. Bioorganic & Medicinal Chenristry, 2010 ,18( 4) : 1626 -1632.
  • 8Ram S, Ehrenkaufer R E. Ammonium formate in organic synthesis: A versatile agent in catalytic hydrogen transfer reductions[J]. Synthesis, 1988, (2) :91 -95.
  • 9Viciu M S, Grasa G A, Nolan S P. Catalytic dehalogenation of aryl halides mediated by a palladiumlimidazolium salt system [J]. Organometallics, 2001 , 20 (16) :3607 -3612.
  • 10Wong L L, Verbalis J G. Vasopressin V2 receptor antagonists [J] . Cardiovascular Research, 2001 ,51 ( 3 ) : 391 -402.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部